StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Net product sales — Total commercial vaccines by Quarter

Net product sales — Total commercial vaccines ($M) ($M)

QuarterlyAnnual

Moderna Net product sales — Total commercial vaccines: $94M in Q2 2026, down 17.5% from a year earlier.

Latest, Q2 2026
94
Period ended Jun 30, 2026
Change on a year earlier
-17.5%
114 in Q2 2025
History
26 quarters
Since Q1 2020
Sources
21
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-07-31) ↗

Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Note 2.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet product sales — Total commercial vaccines ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202694-17.5%Form 10-Q (filed 2026-07-31) ↗
Q1 2026Mar 31, 2026352+309.3%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025646-31.1%Form 10-K (filed 2026-02-20) ↗
Q3 2025Sep 30, 2025973-46.5%Form 10-Q (filed 2025-11-06) ↗
Q2 2025Jun 30, 2025114-38.0%Form 10-Q (filed 2026-07-31) ↗
Q1 2025Mar 31, 202586-48.5%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 2024938-66.4%Form 10-K (filed 2026-02-20) ↗
Q3 2024Sep 30, 20241,820+3.6%Form 10-Q (filed 2025-11-06) ↗
Q2 2024Jun 30, 2024184-37.2%Form 10-Q (filed 2025-08-01) ↗
Q1 2024Mar 31, 2024167-90.9%Form 10-Q (filed 2025-05-01) ↗
Q4 2023Dec 31, 20232,793-42.5%Form 10-K (filed 2026-02-20) ↗
Q3 2023Sep 30, 20231,757-43.7%Form 10-Q (filed 2024-11-07) ↗
Q2 2023Jun 30, 2023293-93.5%Form 10-Q (filed 2024-08-01) ↗
Q1 2023Mar 31, 20231,828-69.1%Form 10-Q (filed 2024-05-02) ↗
Q4 2022Dec 31, 20224,859-29.9%Form 10-K (filed 2025-02-21) ↗
Q3 2022Sep 30, 20223,120-35.1%Form 10-Q (filed 2023-11-03) ↗

Breakdown

What makes up net product sales — Total commercial vaccines

Cite this data

StockData. (2026). Moderna Net product sales — Total commercial vaccines ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rev-product-sales

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.